Overview: HOMA-IR Index TestIntroduction: The HOMA-IR Index Test assesses insulin resistance to diagnose diabetes or metabolic syndrome, helping guide lifestyle or medical interventions for blood sugar control. Affecting 1 in 5 people with obesity, insulin resistance poses diagnostic challenges due to subtle onset. Following 2023 American Diabetes Association (ADA) guidelines, it uses calculation based on insulin and glucose for high accuracy, supporting endocrinology screening. This test is vital for diagnosis, intervention planning, and improving outcomes in endocrinology.
Other Names: Insulin Resistance Test, HOMA-IR Assay.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic reliability.
Historical Milestone: HOMA modeling began in the 1980s with research by Matthews, who developed the index. Calculation refinements in the 2000s by the ADA improved application, surpassing earlier insulin assays.
Purpose: Measures HOMA-IR index to assess insulin resistance, guides lifestyle or medication therapy, and evaluates patients with high blood sugar, aiming to prevent complications.
Test Parameters: HOMA-IR index
Pretest Condition: Fasting required to reflect baseline levels. Collect serum or plasma. Report history of diabetes or obesity.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document high blood sugar or obesity. Include current medications or diet.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cardiovascular disease), and sample collection risks.
Procedural Considerations: Uses calculation based on insulin and glucose levels, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: High index confirms insulin resistance, guiding therapy. Early intervention might prevent progression, while untreated cases lead to diabetes. Normal levels may require glucose tolerance test.
Specialist Consultation: Consult an endocrinologist for interpretation.
Additional Supporting Tests: Fasting glucose, HbA1c, or lipid profile to confirm diagnosis.
Test Limitations: Indirect measure; correlation with clinical status needed. False results possible with beta-cell dysfunction.
References: ADA Guidelines, 2023; Diabetologia, Matthews DR, 2022.
